Custom service
Peptide PEGylation
PEGylate peptides with defined linker length and attachment chemistry
The service is built around site-specific PEGylation at Cys or engineered handles. Depending on the molecule we may move to linear and branched PEG (2–40 kDa) or PEG reagent sourcing and QC to improve stability, loading or yield, and every batch is released with PEGylated peptide with PEG-ratio characterization.
Because Peptide PEGylation projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Half-life extension for candidate peptides
Shielding immunogenic epitopes on conjugates
Clinical PEGylated drug substance
Modifications requiring radiological or BSL-3 containment
Modified peptides are released against a specification that includes site occupancy. Where a modification is labile (sulfation, glycosylation, phosphorylation), we use fragmentation data rather than mass shift alone to assign the site, and we state detection limits for any positional isomers that co-elute.
Service Highlights
- Site-specific PEGylation at Cys or engineered handles as the default route, with linear and branched PEG (2–40 kDa) held as a proven fallback
- PEG reagent sourcing and QC worked into the design where the application requires it
- Modification sites are mapped on the sequence and confirmed by MS/MS before release
- Analytical confirmation of every intermediate before the final release
- Modified and unmodified species are separated and quantified, not just reported
- PEGylated peptide with PEG-ratio characterization delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence & modification map
We annotate every modification site, protection strategy and analytical target before synthesis starts.
Solid-phase assembly
The chain is built with Fmoc chemistry, inserting modified or unnatural residues at the mapped positions.
Modification chemistry
Post-synthesis steps — site-specific PEGylation at Cys or engineered handles, linear and branched PEG (2–40 kDa) — are run under conditions validated on a test cleavage.
Cleavage & purification
Global deprotection and cleavage are followed by RP-HPLC purification to the agreed purity.
Analytical release
Purity, identity and modification ratio are confirmed by HPLC, MS and MS/MS site mapping.
Documentation
PEGylated peptide with PEG-ratio characterization is released with the batch record and analytical package after QC sign-off.
Specifications & timeline
- Turnaround
- 4–6 weeks
- Typical scale
- 0.5 mg – 1 g modified peptide
- Chemistry options
- site-specific PEGylation at Cys or engineered handles; linear and branched PEG (2–40 kDa); PEG reagent sourcing and QC
- Deliverable
- PEGylated peptide with PEG-ratio characterization
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS site mapping, modification ratio
- Shipping
- Ambient or blue ice as stability data dictate
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.